June 24th, 2014
FDA Recalls Another Batch of Generic Metoprolol
Larry Husten, PHD
The FDA has recalled more than 13,000 bottles of metoprolol succinate extended-release tablets manufactured by Dr. Reddy’s Laboratories. In addition, the agency recently recalled another lot of generic metoprolol from a different company, Wockhardt. Both recalls were for medicines manufactured at facilities in India. There have been multiple reports in recent years of problems with generic […]
October 4th, 2013
A New Use for an Old Beta-Blocker?
Borja Ibanez, MD PhD
Borja Ibañez, lead investigator of the METOCARD-CNIC trial, discusses the effect of intravenous beta-blocker use before reperfusion in patients undergoing primary PCI.
October 15th, 2012
Selections from Richard Lehman’s Literature Review: October 15th
Richard Lehman, BM, BCh, MRCGP
This week’s topics include PCI use in states with public reporting of outcomes; proneurotensin as a prognostic marker for CVD, diabetes, and mortality; vorapaxar for secondary prevention of thrombotic events in patients with previous MI; and atenolol vs. metoprolol for hypertension.
August 16th, 2011
Meta-analysis: Beta-Blockers May Be Less Effective in U.S. Than Elsewhere
Larry Husten, PHD
Beta-blockers may not be as effective in the U.S. as in the rest of the world, according to a meta-analysis published in the Journal of the American College of Cardiology. Christopher O’Connor and colleagues analyzed data on patients enrolled in the MERIT-HF, COPERNICUS, CIBIS-II (which did not enroll U.S. patients) and BEST trials. Some 4,200 […]
NEJM Journal Watch — Recent Cardiology Articles- Strategies and Criteria for the Diagnosis and Management of Myocarditis
- Sex-Based Disparity in CABG Outcomes: Are We Moving Toward Parity?
- Can Genetic and Social Risk Scores Improve Cardiac Risk Prediction?
- Extensive Ablation vs. Pulmonary Vein Isolation in Persistent Atrial Fibrillation
- Can a Novel Stent Design Improve Long-Term Outcomes of Percutaneous Coronary Intervention?